Comparison of adverse event in the course of disease between patients treated with or without belimumab
| Factor . | Standard therapy . | Belimumab . | P value . |
|---|---|---|---|
| Number of patient | 112 | 112 | |
| Digestive tract infection | 60 (53.6) | 46 (41.1) | 0.082 |
| Respiratory tract infection | 58 (51.8) | 39 (34.8) | 0.015 |
| Urinary tract infection | 27 (24.1) | 15 (13.4) | 0.059 |
| Leukopenia | 13 (11.6) | 12 (10.7) | 1.000 |
| Mental and neurological adverse events | 28 (25.0) | 20 (17.9) | 0.254 |
| Factor . | Standard therapy . | Belimumab . | P value . |
|---|---|---|---|
| Number of patient | 112 | 112 | |
| Digestive tract infection | 60 (53.6) | 46 (41.1) | 0.082 |
| Respiratory tract infection | 58 (51.8) | 39 (34.8) | 0.015 |
| Urinary tract infection | 27 (24.1) | 15 (13.4) | 0.059 |
| Leukopenia | 13 (11.6) | 12 (10.7) | 1.000 |
| Mental and neurological adverse events | 28 (25.0) | 20 (17.9) | 0.254 |
Values for categorical data, as count (percent).
Comparison of adverse event in the course of disease between patients treated with or without belimumab
| Factor . | Standard therapy . | Belimumab . | P value . |
|---|---|---|---|
| Number of patient | 112 | 112 | |
| Digestive tract infection | 60 (53.6) | 46 (41.1) | 0.082 |
| Respiratory tract infection | 58 (51.8) | 39 (34.8) | 0.015 |
| Urinary tract infection | 27 (24.1) | 15 (13.4) | 0.059 |
| Leukopenia | 13 (11.6) | 12 (10.7) | 1.000 |
| Mental and neurological adverse events | 28 (25.0) | 20 (17.9) | 0.254 |
| Factor . | Standard therapy . | Belimumab . | P value . |
|---|---|---|---|
| Number of patient | 112 | 112 | |
| Digestive tract infection | 60 (53.6) | 46 (41.1) | 0.082 |
| Respiratory tract infection | 58 (51.8) | 39 (34.8) | 0.015 |
| Urinary tract infection | 27 (24.1) | 15 (13.4) | 0.059 |
| Leukopenia | 13 (11.6) | 12 (10.7) | 1.000 |
| Mental and neurological adverse events | 28 (25.0) | 20 (17.9) | 0.254 |
Values for categorical data, as count (percent).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
